Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Fig. 1

Baseline and posttreatment scores at week 12 (a) and week 24 (b) across all 36-item Short Form Health Survey domains compared with age- and sex-matched U.S. general population norms. BP Body pain, GH General health, MH Mental health, PF Physical functioning, RE Role emotional, RP Role physical, SF Social functioning, VT Vitality. p Values show the least-squares mean between-group difference in the change from baseline. p Values provided for week 12 are nominal. Because combined baseline scores are presented, change from baseline for each group cannot be inferred from the figure alone

Back to article page